|Registry of biomedical companies:
  [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 515 active entries
An SBO Co.
Toll free: +011-604-941-9022 (Helpline)
Our Principal has pioneered the concept of transmembrane/compartmentalized processing as applied to animalia through process innovation, modeling for innovation and in vivo/ex vivo direct studies in the ff. areas or fields of study available through the literature:
a) Peptide Nucleic Acid Technology for gene silencing using transcription factor "engineering" (TFE) using transport carriers or porins in microbial cell systems in the rumen stomach of livestock for peptides/amino acids which could spell an advantage in accelerating intracellular transactions both for low concentration free amino acids released through proteolysis at various rates of availability depending on substrate from the animal's diet and/or peptides also made available through digestion that have an effect on microbial cell protein (MCP) synthesis per energy unit (ATP) used (cf. to free amino acids).
b) We have discussed before (see in this portal outlet: Medica & Communications3) elsewhere possible significant advances for cholesterol fighting drugs using PNA Technology through TFE due to compartmentalization of cholesterol flux or titre in bodily fluids in this case in chicken or poultry (e. g. turkeys) shell egg cholesterol storage due to cholesterol transport/esterase activity with the yolk sac and so with the pancreas as it deposits cholesterol ester derivatives as bile into the lower gut effectively lowering bad HDL cholesterol in bodily plasma fluid. These represent two potential areas for further development in controlling cholesterol levels in the body of animalia through our use of simple modeling.
c) Hormones, neurhormones or peptides, vitamins (e. g. VitD) and immunopeptides are all addressable using our PNA Technology through TFE and porins or receptors which would be "gentler" rather than other drug or pharma acting directly on those agents mentioned previously taking their given pool size as such and the boost in porin / receptor pool size in target cell populations. These applications entail addressing reproductive, developmental or growth, occupationally-related or health-related disorders like chronic inflammation (cf. T2Di abetes atherosclerosis, cancers, multiple sclerosis), and immunomodulation in immune functions in animalia including humans.
The author invites further queries for those wishing to pursue Biological Chemistry at SFU.ca (Burnaby) or UBC.ca (Point Grey) from his earlier beginnings in the late '70s early '80s there before transferring out of SFU.ca (Burnaby) for McGill U.
Last update of this entry: July 26, 2020